Introduction
In Bacillus subtilis the genes of pyrimidine nucleotide biosynthesis are organized into an operon, which is regulated by exogenous pyrimidines by transcriptional attenuation at three points in the promoter proximal end of the operon [l-3] . Turner et al. [3] have proposed that transcriptional attenuation is modulated by the protein product of the pyrR gene, which is believed to bind in a pyrimidine nucleotide-dependent fashion to a portion of an antiterminator structure in the pyr mRNA, thereby preventing anti-terminator formation and promoting formation of a downstream transcription terminator structure. Remarkably, PyrR has also been shown to * Corresponding author. Tel.: + 1 (217) 333 3940; Fax: + 1 (217) 244 5858; E-mail: rswitzer@uiuc.edu possess uracil phosphoribosyltransferase activity, even though its deduced amino acid sequence is only very distantly related to those of other bacterial uracil phosphoribosyltransferases [4] . The relationship between the enzymatic activity of PyrR and its ability to function as an RNA-binding attenuation protein is not yet clear.
A detailed study of structure-function relationships with PyrR would illuminate the nature of RNA recognition by this protein, the means by which RNA binding is modulated by pyrimidine nucleotides, and the mechanism of catalysis by this unusual phosphoribosyltransferase. As a first approach to such studies, we have developed a method for the facile selection of pyrR mutants that have defects in the regulation of the pyr operon. Twelve pyr regulatory mutants were isolated and shown by nucleotide sequencing to result from point mutations in the pyrR gene.
Materials and methods

Isolation and characterization of' Parr mutants
The selection used was a modification of the procedure first described by who showed that many revertants of the uracil-sensitive B. subtilis strain JH861 (trpC2 <pa) to uracil tolerance were coordinately derepressed in all of the enzymes of pyrimidine biosynthesis.
Strain JH86 I lacks the arginine-repressible carbamyl phosphate synthetase, but is able to grow on minimal medium lacking arginine, because carbamyl phosphate is supplied by the pyrimidine-repressible carbamyl phosphate synthetase, which is encoded by two genes of the ~YY operon. pvrAA and pyrAB [2] . Thus, when pyrimidines are added to minimal medium, strain JH861 cells are unable to grow, because repression of the pyr operon results in starvation for arginine. JH861 cells grow well when the medium contains both arginine and pyrimidines. Second site revertants of JH861 to pyrimidine tolerance could arise by mutations that cause defects in repression of the ~YY operon. We reasoned that many such mutants would occur in the pyrR gene. Other mutations that might lead to a derepressed phenotype include those that cause defects in the uptake of exogenous pyrimidines or their conversion to the co-repressing metabolite. which is believed to be UMP [1, 3, 6] . We minimized the selection of such mutants by requiring that the pyrimidine-tolerant revertants of strain JH86 1 simultaneously acquire resistance to both uracil and uridine, which enter the cell and are converted to UMP by different pathways [7] . Spontaneous pyrimidine-tolerant revertants of strain JH861 were selected by plating 1 ml of an overnight culture in LB medium [8] on CH minimal medium [9] plates containing 50 pg ml-' each of uracil and uridine and were found at a frequency of approximately 5 X lo-*. After candidate colonies were purified by restreaking on same kind of plates. 12 mutants were chosen for further study. The pyrimidine-tolerant mutants were initially screened for defects in pyrR by scoring the ability of a plasmid carrying intact pyrR gene, pTS 185 [3] , to confer pyrimidine sensitivity when cells transformed with it were grown on CH minimal medium plates containing 50 pg ml -' each of uracil and uridine.
All I2 of the pyrimidine-tolerant mutants from JH86 1 regained pyrimidine sensitivity upon expression of plasmid-borne pyrR gene. Mutants transformed with the pWPl8 vector [IO] remained pyrimidine-tolerant.
Aspartate trunscarbamylasr mssa)
Cell cultures (55 ml) were grown in Spizizen minimal medium [ 1 I] with and without 50 pg uracil and uridine per ml to a cell density corresponding to an optical density at 436 nm of 1.0 and were harvested by centrifugation, washed and resuspended in 5.5 ml of 10 mM Tris HCI/ 1 mM EDTA buffer (pH 8.0). After sonic disruption the cell extract was centrifuged at 16 000 X g for 10 min, and the supernatant was used for assays. Aspartate transcarbamylase activity was determined as described previously [ 12. 131. Protein concentrations were determined with the Coomassie protein reagent (Pierce, Rockford, IL) using bovine serum albumin as the standard protein.
PCR ampl$cation
and DNA sequencing PCR amplification and DNA sequencing were performed with a DNA Thermal Cycler (Perkin Elmer Cetus) as described by the manufacturer. PCR primers used for amplifying a 860-bp chromosomal DNA fragment that included the entire pyrR gene were PyrR-A 1 (5'-CGCGTTCCCGAGGATATGGC-3') and PyrR/Rev (5'-GACCTGCCGAATACTTTT-TGG-3'). Primers for direct sequencing of the 5' to 3' (from the pyr promoter) strand of the PCR-amplified pyrR gene were PyrR/For (5'-CTAAAACC-
PyrR-S 12 (S-GCGCTTGTTGATG-TAGGC-Y), and PyrR-S 13 (5'-CGGGAAAAACAT-CCCGAC-3'). Primers used for sequencing of the 3' to 5' strand of the PCR-amplified pyrR gene were PyrR-S-9R
(5'-GCGTTCGATCATTTCGTG-3') PyrR-A6R
(5'-CAATGCGTTCCGCAAGGCG-3') PyrR-S 11R (5'-CAAGCGGTTCATCGTTGC-3'), PyrR-S 12R (5'-GCCTACATCAACAAGCGC-3'), PyrR-S 13R (5'-GTCGGGATGTTTTTCCCG-3'), and PyrR-S 14R (5'-GCAACCTCTCTGGATTGCCC-3'). All primers were labelled by ['y-32 P]ATPs for direct sequencing of PCR-amplified products, and the se-quence of the pyrR mutant DNAs was determined for both strands [ 141 with the jinol'" Sequencing System (Promega, Madison, WI). 32 P-Labelled DNA fragments were separated on 6% polyacrylamide-35% formamide gels.
Results and discussion
Table 1 describes 12 independently isolated pyrimidine-tolerant mutants derived from strain JH861. All 12 strains were converted to pyrimidine sensitivity by transformation with a plasmid bearing the pyrR gene, but not by the vector plasmid. Aspartate transcarbamylase assays demonstrated that all of the mutant strains were strongly derepressed in pyrB expression and were resistant to repression by exogenous pyrimidines.
Sequencing the DNA encoding PyrR from each of these mutants confirmed that each mutant resulted from a single point mutation in the pyrR gene (Fig.  1) . Three of the 12 mutations presumably act by preventing formation of significant amounts of the PyrR protein. BGHS and BGH18 were translation termination mutants occurring at codons near the N-terminus of PyrR. BGH17 resulted from a mutation in the ribosome binding site for pyrR. It is somewhat surprising that such a mutation in the ribosome binding site would reduce formation of PyrR to such a low level as to obliterate regulation. This may reflect the fact that the translation initiation codon for PyrR is a rare UUG codon, which would be expected to be unusually sensitive to changes in the ribosome binding site that reduce the affinity of the mRNA for the ribosome.
The remaining nine mutations were missense mutations in the pyrR coding sequence (Fig. 1) . One of these mutations was independently isolated three times (BGH4, 14, and 19). The biochemical basis for this mutation is readily rationalized. It results in the replacement of a highly conserved Asp residue in the PRPP binding domain of the protein with a Tyr residue (Fig. 2) . Originally identified as of probable functional significance because of its invariant occurrence in the amino acid sequences of many phosphoribosyltransferases and PRPP synthetases [ 151, this residue is now known from x-ray crystallographic analysis of the structures of glutamine PRPP amidotransferase [ 161 and orotate phosphoribosyltransferase [17] to interact specifically with the ribofuranosyl ring of PRPP and nucleotides bound to the active site of these enzymes. Thus, the Asp-to-Tyr mutant of PyrR would almost certainly fail to bind the nucleotide substrate UMP and would render the protein unable to respond to the co-repressing metabolite. Five other unique mutations were identified (Fig.  1) . Interestingly, these mutations were distributed throughout the length of the coding sequence. Too little is yet known about the structure of PyrR for us to suggest a biochemical basis for their defects in regulation of the pyr operon, but when the sequences of the four known members of the PyrR family are aligned and the locations of the mutations are viewed in light of the alignment (Fig. 2) , it appears that they occur in or very near to conserved residues. Further interpretation is difficult, because two members of the family, the PyrR sequences from Haemophilus influenzae [ 181 and from a Synechocystis species [19] , have been identified on the basis of their deduced amino acid sequences only, and it is not known whether they possess either uracil phosphoribosyltransferase activity or the ability to act as RNA-binding attenuation proteins.
We are developing procedures for the facile subcloning and overexpression of these and other mutant PyrR proteins, so that defects in their uracil phosphoribosyltransferase activity or ability to bind to pyrimidine nucleotides or pyr mRNA can be investigated directly. The three-dimensional structure of PyrR is also being determined by x-ray crystallographic analysis, so that a detailed structure-function analysis based on the regulation-deficient mutants readily isolated as described in this work will soon be possible.
It may seem surprising that all of the mutants with defects in the regulation of repression of the pyr operon were in the pyrR gene and that none were found in the DNA specifying the attenuator regions of the operon. We believe that this result is, in fact, exactly what should be expected. This is because the action of three tandem attenuators is required to fully repress the genes encoding the enzymes of UMP biosynthesis [ 1, 3] . Thus, a mutation in a single attenuator region would probably not lead to total loss of regulation; loss of regulation would require two or three simultaneous mutations in the attenuators, which would surely be much more rare than a single mutation in the pyrR gene. Finally, it should be noted that the selection we have used to isolate PyrR mutants could be readily modified to screen for B. subtilis mutants with defects in either uracil or uridine uptake and conversion to UMP.
